43 results about "Liver necrosis" patented technology

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

The present application relates to the technical field of medicine, and discloses application of gastrodin in preparation of medicine for preventing and treating radioactive liver injury, wherein the radioactive liver injury is liver injury caused by ionizing radiation exposure. It is found that the gastrodin can effectively intervene in specific mechanism of the radioactive liver injury, significantly reduce the mortality of the radioactive liver injury mice, reverse the hepatic veno-occlusive disease and the core pathological features of liver fibrosis of the radioactive liver injury, and more specifically treat the radioactive liver injury. On the other hand, the gastrodin can be used before radiation exposure to prevent serious radioactive liver injury after radiation exposure.

The invention discloses an application of harpagoside in preparation of a medicine for preventing and / or treating hepatic fibrosis. The invention discloses an application of harpagoside in preparation of a health care product with an auxiliary protection effect on chemical liver injury. The animal level proves that the harpagoside can reduce hepatic fibrosis such as chemical hepatic fibrosis induced by carbon tetrachloride, reduce liver collagen deposition, reduce hydroxyproline content in hepatic tissue, reduce increased HA and Col IV content in serum, and reduce expression of fibrosis and collagen deposition related genes, so that the harpagoside can be used for treating hepatic fibrosis. The traditional Chinese medicine composition has a good effect of treating or preventing hepatic fibrosis.

The invention discloses an application of 5-methoxyl serotonin in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and systematically proves that the 5-methoxyl serotonin (5MOS) has the effects of relieving hepatic fibrosis, improving accumulation of bile acid in the liver and reversing metabolism and transport of the bile acid for the first time, so that the cholestatic liver diseases can be prevented and / or treated by the 5-methoxyl serotonin (5MOS). DDC-induced cholestatic liver injury is relieved in a dose-dependent manner, and a new medication strategy is provided for treating cholestatic liver diseases.

The application belongs to the technical field of biomedicine, and discloses a method for constructing a Channa argus bile stasis model. The application discloses application of rifampicin or a pharmaceutically acceptable salt thereof in construction of a fish liver injury model. The application discloses, for the first time, that the antibiotic rifampicin widely used in aquaculture is used to construct a fish liver injury model. The model is closer to the real scene of the use of a large amount of drugs when bacterial diseases break out in production practice. The injury type of the fish liver injury model is clearly directed to bile stasis, which fills the research blank of the disease model of the fish, and is different from common hepatocyte necrosis or fatty liver models.

The present application relates to a kind of VSIG4 based on reversible immunological affinity magnetic bead separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation + The present application provides a method for isolating VSIG4-positive macrophages, which uses reversible immunological affinity magnetic beads coupled with anti-VSIG4 antibodies to contact with a sample, and enriches VSIG4-positive macrophages by magnetic separation The isolated cells of the present application can reduce liver inflammation and injury, and effectively treat acute liver injury and acute liver failure. The isolation method of the present application is fast, mild and efficient, and the obtained cells are functional and suitable for adoptive cell therapy, which has a broad clinical application prospect.

The present invention discloses the use of an acetyl-CoA (Ac‑CoA) promoter in the preparation of a drug for promoting liver regeneration. The present invention utilizes a mouse partial hepatectomy model and administers GS‑0976 before hepatectomy to increase Ac‑CoA in the liver. The results show that increased Ac‑CoA in the liver has the ability to improve liver function after liver injury and promote hepatocyte proliferation. The mechanism involves Ac‑CoA promoting MSL1 phase separation, increased STAT3 and H4K16 acetylation, which manifests as significantly upregulated cell cycle-related genes and increased hepatocyte proliferation. The experimental results show that increasing liver Ac‑CoA levels has the effect of promoting liver regeneration, providing a new solution for the recovery and treatment of hepatectomy and its complications.

Disclosed in the present invention are an iodine-131-labeled small-molecule polypeptide TFMP-Y2, and a preparation method therefor and the use thereof. In the present invention, on the basis of the Caerin 1.9 polypeptide and by performing modification to enhance the water solubility of the polypeptide and reduce the inhibitory effect of the polypeptide on the proliferation of normal cells, a new small-molecule polypeptide TFMP-Y2 is obtained. The TFMP-Y2 polypeptide alone has no significant inhibitory effect on the proliferation of normal cells and HGC-27. However, 131I-TFMP-Y2 can be stably retained in gastric carcinoma cells, and has a significant anti-tumor effect. Moreover, the water-soluble 131I-TFMP-Y2 is mainly excreted by the renal urinary system, such that the risk of radioactive liver damage caused by 131I-Caserin 1.9 can be reduced. Therefore, TFMP-Y2 is a good small-molecule polypeptide for introducing a nuclide into the body, which improves the drug safety and the tumor targeting property, and can be used as a potential drug for internal radiation therapy of tumors.

The invention relates to the field of biological medicines, and discloses application of an OGG1 micromolecule agonist in preparation of a medicine for treating liver inflammatory diseases. According to the micromolecule TH10785, by activating the beta, delta-lyase activity of DNA repair enzyme OGG1, the oxidized DNA repair capacity is remarkably enhanced, ROS accumulation in liver cells is reduced, NF-kappa B signal channel activation and proinflammatory factor release are inhibited, and therefore liver inflammation and fibrosis are effectively relieved. Meanwhile, the medicine can inhibit the activation of B cells and the formation of plasma cells, finally reduces the generation of autoimmune antibodies, and improves the immune imbalance state of autoimmune hepatitis. The invention provides an innovative treatment strategy based on OGG1 enzyme function amplification, and a new pharmacological approach is provided for treatment of chronic liver diseases and immunological liver injury.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

The invention discloses application of an APOA5 inhibitor in prevention and treatment of PD-L1 high expression liver diseases and screening of drugs for regulating liver immune inflammatory microenvironment homeostasis. The APOA5 inhibitor reduces and / or inhibits at least one of expression, secretion and activity of APOA5. The application finds that the expression level of PD-L1 (especially the expression level of macrophage PD-L1) is reduced by knocking down APOA5, and the APOA5 can be applied to reduction of liver cell apoptosis, reduction of the level of macrophage inflammatory factors and prevention and treatment of PD-L1 high-expression related diseases such as sepsis acute liver injury.

The invention discloses application of solamargine in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. By simulating a classical Mdr2- / -mouse model of clinical cholestasis pathology, the solamargine is researched and proved to treat cholestatic liver injury by improving hepatocyte injury, bile duct dysfunction and bile metabolism disorder, and the solamargine shows good application potential in clinical treatment of cholestatic liver diseases.

The present application belongs to the technical field of medicine, and relates to a kind of pharmaceutical composition and its application in preparation for treating or preventing liver fibrosis drug. A kind of pharmaceutical composition for treating or preventing liver fibrosis, the pharmaceutical composition includes as active ingredient the protocatechuic acid (PCA) and gimalin (GER). The present application first confirms that protocatechuic acid and gimalin combined application has significant synergistic effect in the treatment of liver fibrosis, and its curative effect is better than any single compound single administration, can more effectively reduce liver injury index, improve liver pathological morphology, reduce intrahepatic collagen deposition. Based on its clear mechanism of action, the composition of the present application is especially suitable for treating liver fibrosis related to abnormal expression of RIPK3.

The invention discloses a biomarker composition and application thereof. The biomarker combination comprises a hepatitis B capsid antibody complex and glutamic-pyruvic transaminase. The biomarker combination provided by the invention has high specificity and sensitivity when being used for diagnosing chronic hepatitis B, predicting prognosis of chronic hepatitis B and / or evaluating liver injury caused by chronic hepatitis B. If ALT is normal (llt; according to the present invention, the potential intrahepatic inflammation can still be significantly detected in chronic hepatitis B patients (e.g., 40 IU / L) patients, can be adopted as the non-invasive biomarker for evaluating the hepatic inflammation in chronic hepatitis B patients, and can accurately reflect the intrahepatic inflammation level of chronic hepatitis B patients so as to provide the effective basis for the start of the antiviral treatment.

The present application relates to the technical field of biotechnology, and particularly relates to a lysosome-targeted calcium ion fluorescent probe and application thereof. The calcium ion fluorescent probe provided by the present application has high sensitivity fluorescent response to calcium ions, and is not interfered by pH, and can be used for monitoring dynamic changes of lysosome calcium ions. Meanwhile, the lysosome calcium ion fluorescent probe in the present application has good biocompatibility, low background fluorescent interference and other advantages, makes up for the deficiency of traditional commercialized calcium ion fluorescent probes, and has wide application prospect in the field of acute liver injury and other liver diseases in vivo.

The present invention discloses the use of fotantinib in treating severe dengue fever liver damage, belonging to the field of biotechnology. The present invention provides the use of fotantinib or a pharmaceutically acceptable salt thereof in preparing a pharmaceutical composition for preventing or treating dengue fever liver damage, and in preparing a pharmaceutical composition for regulating the carbon metabolism of hepatocytes in patients infected with dengue virus. The present invention also provides a method for regulating the level of in vitro dengue virus-infected hepatocyte damage, and for screening a pharmaceutical method for assisting fotantinib or a pharmaceutically acceptable salt thereof in treating and preventing dengue fever liver damage.

This invention relates to the field of biomedicine, specifically to the application of dimethylhydroquinone in improving ischemia-reperfusion-related injury of the heart and liver. 2,6-DMHQ can reduce serum ALT and AST, improve liver necrosis, and also reduce serum myocardial enzyme levels CK, CK / MB, and LDH, thereby reducing the area of ​​myocardial infarction.

The invention relates to the technical field of medicines, and discloses application of gastrodin in preparation of a medicine for preventing and treating radioactive liver injury, and the radioactive liver injury is liver injury caused by ionizing radiation exposure. The gastrodin is found to be capable of effectively intervening a specific mechanism of the radiation-induced liver injury, so that the death rate of mice with the radiation-induced liver injury is remarkably reduced, meanwhile, the core pathological characteristics of hepatic vein occlusion and hepatic fibrosis of the radiation-induced liver injury are reversed, and the radiation-induced liver injury is treated in a more targeted manner. On the other hand, gastrodin is used before radiation exposure, so that serious radioactive liver injury after radiation exposure can be prevented.

According to a sepsis mouse model, it is found that phytolaccin can reduce the liver necrosis area and the inflammatory focus caused by sepsis by reducing the content of alanine aminotransferase, glutamic oxalacetic transaminase, serum creatinine and lactic dehydrogenase, so that the application of phytolaccin to preparation of the medicine for treating sepsis is achieved, and the application of phytolaccin to preparation of the medicine for treating sepsis is achieved. The lung inflammation, alveolar wall thickening and inflammatory cell infiltration are improved, so that the organ injury caused by sepsis is relieved. Meanwhile, the phytolaccin can also regulate the polarization state of macrophages to a balanced state in an inflammatory storm state, so that the release of proinflammatory factors is inhibited, and the effect of preventing and treating sepsis is achieved.

The present disclosure relates to a new water-soluble fullerene derivative and a preparation method thereof, and application of the water-soluble fullerene material in preventing and treating liver damage / liver failure. The fullerene material of the present disclosure can efficiently scavenge active free radicals, reduce liver oxidative stress, restore normal liver function indicators, reduce liver necrosis, and prevent and treat drug-induced liver damage / liver failure.

The present invention discloses an ultra-sensitive fluorescent small molecule probe for biothiols, a preparation method thereof, and an application thereof. The present invention proposes a dual fluorescence quenching mechanism combining the PET effect and the "ester to carboxylic acid" conversion strategy to construct an MCB-NBD probe with "zero" intrinsic fluorescence. The small molecule fluorescent probe MCB-NBD of the present invention overcomes the problems of high background fluorescence, low sensitivity, and high detection limit of existing small molecule fluorescent probes. The fluorescent small molecule probe MCB-NBD of the present invention exhibits a very low detection limit for biothiols. When 200nM biothiols are added, the fluorescence response multiple exceeds 3 times, and it can significantly distinguish between liver-damaged plasma and normal plasma at 80-fold dilution. The fluorescent small molecule probe MCB-NBD of the present invention monitors the fluctuation of biothiols in dihydroartemisinin-induced ferroptosis, reflecting the application prospect of the present invention in studying new strategies for clinical tumor treatment.

The invention discloses bifidobacterium bifidum for improving acute liver injury induced by acetaminophen and application of the bifidobacterium bifidum, and belongs to the technical field of microorganisms. The invention provides bifidobacterium bifidum for improving acute liver injury induced by acetaminophen, and the preservation number of the strain is CGMCC No.29545. Animal experiments prove that the bifidobacterium bifidum subspecies can improve the serum liver enzyme level and large-area liver necrosis of mice with acute liver injury caused by acetaminophen, and can improve the acute liver injury caused by acetaminophen. Oxidative stress caused by mitochondrial damage is relieved, and apoptosis and inflammatory response of cells are reduced. The traditional Chinese medicine composition can safely and obviously improve the acute liver injury, and has certain significance for clinically promoting probiotic treatment.

The invention discloses an application of CA170 in preparation of a medicine for treating echinococcus multilocularis, and aims to realize effective treatment on echinococcus multilocularis infection. C57 / 6J mice infected by hepatic portal veins for 40 days through alveolar coccosis serve as research objects, CA-170 micromolecules are orally administrated, the dosage of CA-170 in the medicine is not lower than 10 mg / kg, the CA-170 is treated once every three days for one month, and the drug effect of CA-170 on protoscolex cystic development and focus growth in the bodies of the echinococcus multilocularis infected mice is detected. Results show that compared with a solvent control group, in-vivo focuses of mice in a CA-170 treatment group are reduced, and the number and the weight of echinococcosis cysts are remarkably reduced, indicating that CA170 shows a good effect in the aspect of resisting echinococcosis multilocularis infection, and can reduce the proportion of MDSC caused by the infection and relieve liver injury caused by the infection. According to the application scheme provided by the invention, technical support is provided for efficiently preventing and treating the echinococcosis multilocularis, and a foundation is laid for clinical treatment of the CA-170 on the echinococcosis multilocularis.

The invention discloses application of peptidoglycan in preparation of a hepatocyte mitochondrial autophagy inducer, and belongs to the technical field of biological medicine. The invention finds that a bacterial cell wall component peptidoglycan can activate autophagy of damaged mitochondria. Experiments prove that the peptidoglycan serving as the bacterial cell wall component can activate mitochondrial autophagy to remove damaged mitochondrial, further inhibit liver fibrosis and effectively relieve liver injury, so that the peptidoglycan serving as the bacterial cell wall component can be used for preparing the medicine for activating mitochondrial autophagy.

The invention discloses an application of parabacteroides dielsii outer membrane vesicles in preparation of a medicine for treating hepatic fibrosis. The invention successfully prepares, extracts and systematically characterizes the outer membrane vesicles (OMV) derived from parabacteroides dielsii for the first time, and verifies the therapeutic potential of the OMV in a CCl4-induced liver injury and fibrosis model. Experimental results show that the OMV intervention significantly improves the pathological structure of liver tissue and significantly reduces collagen deposition, so that the OMV intervention is expected to become a novel treatment strategy for hepatic fibrosis.

The invention discloses a liver small molecule peptide as well as a preparation method and application thereof, and belongs to the technical field of functional peptides. The small molecule peptide prepared by the preparation method provided by the invention effectively retains active factors in animal livers, can stimulate rapid proliferation of hepatocytes, and can reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in serum of mice with liver injury in a short time; necessary raw materials can be continuously provided for liver cell regeneration, and the liver-protecting composition has a good application prospect in protecting liver health and maintaining / recovering damaged liver functions; the beverage is fragrant, sweet, fine and smooth in taste, free of unpleasant odor, free of preservatives, free of toxic and harmful substances, high in safety and wide in applicable crowd.

The invention provides a recombinant adeno-associated virus vector, a product and application of the recombinant adeno-associated virus vector to treatment of hemophilia A, and belongs to the technical field of biological medicine. A recombinant AAV vector is prepared on the basis of an hFVIII nucleotide sequence with B structural domain deletion as shown in SEQ ID NO.1 or SEQ ID NO.2 or an optimized nucleotide variant sequence, the recombinant AAV vector has the characteristic of targeting liver, a human VIII factor gene can be delivered to liver cells of a patient diagnosed as type A hemophilia by using a replication-deficient adeno-associated virus, and the human VIII factor gene is promoted to be efficiently expressed, so that the recombinant AAV vector can be used for treating the type A hemophilia. The use dosage is not higher than 2 * 10 < 13 > vg / kg, and the risk of liver injury caused by high dosage is avoided from the source. The hemorrhage symptom of hemophilia patients can be relieved, a brand new technical normal form is provided for the A-type hemophilia from symptomatic blood transfusion to safer and more effective gene therapy, and the development of precise treatment of hereditary blood coagulation disorder diseases is promoted.

The invention provides an application of selenium-rich probiotics in preparation of a preparation for treating fluoxetine-induced liver injury, and relates to the technical field of biological medicine, the application is characterized in that Se-BL is obtained by reducing sodium selenite through ascorbic acid and modifying the surface of bifidobacterium longum, and nano-scale selenium dots are formed. The preparation plays a role through dual mechanisms: active oxygen (ROS) is directly removed, an Nrf2 pathway is activated, and the liver oxidation resistance (GSH, SOD) is improved; the traditional Chinese medicine composition is capable of inhibiting NF-kappa B inflammation signal channels, reducing proinflammatory factors (TNF-alpha and IL-6) and synchronously regulating intestinal flora so as to enhance the intestinal barrier function. Experiments prove that the traditional Chinese medicine composition can remarkably reduce the level of serum transaminase (ALT / AST / ALP) and relieve liver tissue necrosis and lipid peroxidation damage (MDA), the dosage form of the traditional Chinese medicine composition is an oral preparation, and each dose of the traditional Chinese medicine composition contains 1 * 10 <-1 > * 10 <-1 > CFU of Se-BL viable bacteria. The selenium-modified probiotics are used for antagonizing hepatotoxicity of mental drugs for the first time, and an innovative therapy is provided for fluoxetine-induced drug-induced liver injury (DILI) and acute hepatic failure (ALF).